アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
A synthetic peptide corresponding to residues in the N terminal of human MKK6.
Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.
A trial size is available to purchase for this antibody.
Our Abpromise guarantee covers the use of ab33866 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Detects a band of approximately 36 kDa (predicted molecular weight: 37 kDa).|
Lanes 1, 5 and 9: Wild-type HAP1 cell lysate (20 µg)
Lanes 2, 6 and 10: MEK6 knockout HAP1 cell lysate (20 µg)
Lanes 3, 7 and 11: HeLa cell lysate (20 µg)
Lanes 4, 8 and 12: A431 cell lysate (20 µg)
Lanes 1, 2, 3 and 4: Green signal from target – ab33866 observed at 37 kDa
Lanes 5, 6, 7 and 8: Red signal from loading control – ab18058 observed at 130 kDa
Lanes 9, 10, 11 and 12: Merged (red and green) signal
ab33866 was shown to specifically react with MEK6 when MEK6 knockout samples were used. Wild-type and MEK6 knockout samples were subjected to SDS-PAGE. ab33866 and ab18058 (loading control to Vinculin) were diluted 1/10 000 and 1/2000 respectively and incubated overnight at 4ºC. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) ab216776 secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.
ab33866 has not yet been referenced specifically in any publications.